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Abstract
Background: The EMPOWER trial aimed to assess the effects of a 9-week exercise prehabilitation programme on
physical fitness compared with a usual care control group. Secondary aims were to investigate the effect of (1) the
exercise prehabilitation programme on psychological health; and (2) neoadjuvant chemoradiotherapy (NCRT) on
physical fitness and psychological health.
Methods: Between October 2013 and December 2016, adults with locally advanced rectal cancer undergoing
standardised NCRT and surgery were recruited to a multi-centre trial. Patients underwent cardiopulmonary exercise
testing (CPET) and completed HRQoL questionnaires (EORTC-QLQ-C30 and EQ-5D-5L) pre-NCRT and post-NCRT
(week 0/baseline). At week 0, patients were randomised to exercise prehabilitation or usual care (no intervention).
CPET and HRQoL questionnaires were assessed at week 0, 3, 6 and 9, whilst semi-structured interviews were
assessed at week 0 and week 9. Changes in oxygen uptake at anaerobic threshold (VO2 at AT (ml kg
−1 min−1))
between groups were compared using linear mixed modelling.
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Results: Thirty-eight patients were recruited, mean age 64 (10.4) years. Of the 38 patients, 33 were randomised: 16
to usual care and 17 to exercise prehabilitation (26 males and 7 females). Exercise prehabilitation significantly
improved VO2 at AT at week 9 compared to the usual care. The change from baseline to week 9, when adjusted for
baseline, between the randomised groups was + 2.9 ml kg −1 min −1; (95% CI 0.8 to 5.1), p = 0.011.
Conclusion: A 9-week exercise prehabilitation programme significantly improved fitness following NCRT. These
findings have informed the WesFit trial (NCT03509428) which is investigating the effects of community-based
multimodal prehabilitation before cancer surgery.
Trial registration: ClinicalTrials.gov NCT01914068. Registered 1 August 2013.
Keywords: Exercise prehabilitation, Neoadjuvant cancer treatment, Physical fitness, Rectal cancer, Surgery
Background
The standard multi-modal treatment with curative intent
for magnetic resonance imaging (MRI)-defined, resec-
tion margin-threatened, locally advanced rectal cancer is
long course neoadjuvant chemoradiotherapy (NCRT)
followed by a waiting period before surgery (NICE
2020). However, some centres in the UK prefer a multi-
modal treatment pathway of systemic neoadjuvant
chemotherapy prior to NCRT followed by a waiting
period before surgery or even short course NCRT with a
much shorter wait period before surgery. Although such
multimodal treatment pathways have improved cancer
outcomes mainly by reducing local recurrence rates
(Fanke et al. 2018; Pucciarelli et al. 2009), they are asso-
ciated with a risk of toxicity and a significant risk of
morbidity and mortality (Pearse et al. 2012).
There is strong evidence that cardiopulmonary exer-
cise testing (CPET) predicts post-operative morbidity
and mortality in several surgical groups (Carlisle and
Swart 2007; Lee et al. 2018; Moran et al. 2016; Snowden
et al. 2010; Wijeysundera et al. 2018; Wilson et al. 2010).
In people with newly diagnosed rectal cancer, NCRT
prior to surgery has been shown to significantly reduce
physical fitness, as measured by CPET, and this reduc-
tion has been linked to adverse post-operative outcome
(West et al. 2014a). The standard waiting period be-
tween completion of NCRT and surgery is generally at
least 8 weeks (Du et al. 2017) (or in some Na-
tional Health Service (NHS) hospitals up to 14 weeks)
and therefore represents a unique opportunity to inter-
vene with exercise prehabilitation. In this area of re-
search, early evidence demonstrates the feasibility and
preliminary effectiveness of exercise training (unimodal
prehabilitation delivered in varied formats) for people
with rectal cancer scheduled for NCRT and surgery
(Heldens et al. 2016; Morielli et al. 2016a; Morielli et al.
2016b; Morielli et al. 2018a; Moug et al. 2019; Singh
et al. 2018; West et al. 2014b). To date, however, no ex-
ercise RCTs have been reported on both physical and
psychological health measures in people with rectal
cancer (although the EXERT trial is currently recruiting)
(Morielli et al. 2018b) or indeed any patient group
scheduled for a multimodal treatment pathway (Lough-
ney et al. 2018).
The primary aim of the EMPOWER trial was to assess
the effects of a 9-week exercise prehabilitation programme
on physical fitness, compared with a usual care control
group. Secondary aims were to investigate the effects of
(1) the exercise prehabilitation on psychological health
and (2) NCRT on physical fitness and psychological
health. Other exploratory outcomes included physical ac-




The methodology for the EMPOWER trial has been
published elsewhere (Loughney et al. 2016), registered
with ClinicalTrials.gov NCT01914068 (registered 1
August 2013, https://clinicaltrials.gov/ct2/show/NCT01
914068). EMPOWER is a multi-centre trial which was
conducted in five UK NHS hospitals. Briefly, this was a
parallel group (exercise prehabilitation vs. usual care
control), observer blinded (blind to CPET data, group al-
location and outcomes), randomised controlled clinical
trial. Patients with MRI-defined, circumferential margin-
threatened, potentially curable, locally advanced rectal
cancer undergoing both NCRT and elective surgery were
recruited. All potentially eligible patients were identified
at multi-disciplinary meetings and approached at an out-
patient appointment. Patients were contacted by tele-
phone to provide additional information about the trial.
Written informed consent was provided at the pre-
NCRT visit. Recruitment took place between 2013 and
2016.
Neoadjuvant cancer treatment
Neoadjuvant cancer treatments varied depending on the
hospital. The ‘standard’ chemoradiotherapy programme
was 45 Gy in 25 fractions on weekdays using a 3D
Loughney et al. Perioperative Medicine           (2021) 10:23 Page 2 of 12
conformal technique with CT guidance and oral capecit-
abine 900 mg m−2 twice daily on radiotherapy days. Al-
though the role of neoadjuvant systemic chemotherapy
is still under investigation (Habr-Gama et al. 2009;
Nilsson et al. 2013; Wyrwicz et al. 2016), during recruit-
ment to the EMPOWER trial, University Hospital
Southampton NHS Foundation Trust and Royal
Bournemouth Christchurch Hospitals adopted systemic
neoadjuvant chemotherapy prior to chemoradiotherapy
as a standard treatment. Eight participants were sched-
uled for this treatment which consisted of oxaliplatin
130 mg m−2 intravenously on day 1, oral capecitabine
1000 mg m−2 (days 2–15) given in a 3 weekly cycle × 4
cycles over 12 weeks, followed the standard chemoradio-
therapy programme as described above.
Randomisation
Following neoadjuvant CRT (week 0), patients were allo-
cated to the in-hospital exercise training group or usual
care control group. Patients were randomised (1:1) to ei-
ther an in-hospital exercise prehabilitation programme
or usual care control group using the Trans European
Network for patient randomisation in clinical trials sys-
tem (TENAELA System) and concealed by the research
team.
Interventions
Usual care control group
The usual care control group received routine care
throughout their cancer pathway from diagnosis to sur-
gical resection (no exercise intervention).
Exercise prehabilitation intervention group
Participants started their exercise training on the first
week after NCRT (week 0) in their treating hospital and
were scheduled to attend 3 sessions/week for 9 weeks.
The delivery of the exercise programme is described
elsewhere (Loughney et al. 2016) and in Supplementary
Appendix 1 according to the Consensus on Exercise
Reporting Template guidelines (Slade et al. 2016).
Exercise training adherence
Exercise adherence was assessed by number of sessions
attended compared to number of planned sessions (i.e. 3
sessions/week × 9 weeks)
Outcome measurements
All patients were assessed pre-NCRT, after completion
of NCRT (week 0/baseline) and at weeks 3, 6 and 9.
Primary outcome
Physical fitness
The CPET-derived variable, oxygen uptake at anaerobic
threshold (VO2 at AT (ml kg
−1 min −1), was used to
assess physical fitness at all time points. CPET data was
reported according to the Perioperative Exercise Testing
and Training Society (POETTS) guidelines (which were
co-developed by authors SJ and MPG) (Levett et al.
2018). The CPET protocol was identical at each hospital
(described elsewhere (Loughney et al. 2016)) using the
same software and the same metabolic cart (Geratherm
Respiratory BmbH, Love Medical Ltd.). Final CPET ana-
lysis was conducted using the modified V-Slope method
by two independent physiological assessors blinded to
group allocation, each other and clinical outcomes. Any
discrepancies (variance by more than 5% in VO2 at AT
between the first two assessors) were resolved by a third
assessor.
Secondary outcome
Health-related quality of life (HRQoL)
HRQoL was assessed by the following:
(1) Semi-structured interviews: at week 0 (following
NCRT) and at week 9 (prior to surgery) to explore
patients’ perspectives of their HRQoL using
methods previously piloted by our group (Fit-4-
Surgery) (Burke et al. 2013).
(2) Questionnaires: the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30; 30 items)
(Aaronson et al. 1993) and EQ-5D-5L (Rabin and




Daily physical activity was measured using a multi-
sensory accelerometer (SenseWear Pro® armband (Model
MF-SW, display model DD100); BodyMedia, Inc.,
Pittsburgh, PA, USA). Monitors were issued to partici-
pants at their CPET visits. Participants were asked to
wear the monitor for three consecutive days and nights
(72 h of continuous data). Outcome measures of interest
for physical activity were daily step count and sleep
efficiency.
Post-operative morbidity survey (POMS)
Post-operative outcome was objectively recorded using
POMS (Grocott et al. 2007) at days 3, 5, 8 and 15.
Cancer staging
Rectal cancer tumour regression was quantified by MRI
assessment using the MRI-based T-staging tumour re-
gression grade (ymrTRG) utilizing the MERCURY group
protocol (Patel et al. 2011, 2012) and the histopatho-
logical tumour regression grading (ypTRG) (Dworak
et al. 1997).
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Safety
All adverse events to CPET or the exercise prehabilita-




A sample of 46 patients was required to detect a differ-
ence between groups of 2.0 ml kg−1 min−1 VO2 at AT
using a two-sample t test at the 5% significance level
with 90% power. This was based on a standard deviation
of the change in VO2 at AT of 1.8 ml kg
−1 min−1 and
was inflated to allow for 20% patient drop-out (Koth-
mann et al. 2009).
Statistical analyses
Descriptive analyses were carried out to summarise pa-
tients’ characteristics. Continuous variables are reported
as mean (SD) or median and inter-quartile range (IQR),
depending on distribution, and categorical variables as
frequency (%). The Shapiro-Wilk test for normality of
distributions was applied. Estimates obtained from statis-
tical tests are reported with 95% CI. The effect of NCRT
on physical fitness was assessed using a paired t test.
The primary analysis was intention to treat. For the
primary outcome of VO2 AT, all randomised partici-
pants with baseline (week 0) were included. Multiple im-
putation was used to handle any missing outcome data
for the primary endpoint.
A linear regression model (using age and gender) was
used to investigate the effect of the exercise prehabilita-
tion intervention on physical fitness and a 95% confi-
dence interval on the mean difference between the two
groups for both unadjusted and baseline-adjusted
models. In order to assess the sensitivity of results to co-
variates, a further ‘adjusted’ effect was calculated using
linear regression with age and gender as covariates (Belle
2002). Linear mixed modelling was employed to com-
pare fitness over all time points.
Linear regression models were used to compare overall
HRQoL scores between groups and EORTC QLQ-30
sub-scales, and multilevel mixed effects ordinal regres-
sion was used to assess EQ-5D-5L sub-scales. Interview
data were analyzed using a thematic framework ap-
proach (Burke et al. 2013).
The effect of exercise prehabilitation on physical activ-
ity was analysed in the same way as physical fitness.
Cancer staging was reported as tumour, node metastasis
version 5 (TNM) staging with T3 sub-staging, Response
Evaluation Criteria in Solid Tumours (RECIST) and
ymrTRG (Glimelius et al. 2010). Pathological outcomes
were graded according to the pathological tumour re-
gression grading (ypTRG) and ypTNM. In our protocol
paper (Loughney et al. 2016), we stated that we would
conduct univariate logistic regression analysis to analyse
the association between demographic variables (patient
age and sex), MRI parameters, and pathologic tumour
response, to enable the calculation of odds ratios for the
probability of an unfavourable pathological outcome,
and to analyse the sensitivity, specificity, positive and
negative likelihood ratios. However, because of low
number of participants in each group who completed
NCRT and surgery, this analysis was not performed.
Results
Between October 2013 and December 2016, 78 patients
met the inclusion criteria and 38 agreed to participate
(Fig. 1). Of the 38 patients recruited, 15 were from Uni-
versity Hospital Southampton NHS Foundation Trust,
12 from Aintree University Hospitals NHS Foundation
Trust, four from South Tees Hospitals NHS Foundation
Trust and seven from Royal Bournemouth Christchurch
Hospitals. Thirty-three were randomised (16 to the usual
care control group and 17 to the exercise prehabilitation
group), 25 completed the follow-up assessment at week
9 and 21 underwent surgery. Patient characteristics are
presented in Table 1. Sixteen participants received neo-
adjuvant chemotherapy prior to the standard NCRT
regimen whilst the remainder received the standard
NCRT regimen. Adherence to the 9-week exercise
programme was 91% and the exercise programme was
adapted and progressed every 3 weeks for all participants
based on repeat CPET assessments.
Primary outcome
Physical fitness
The change in VO2 at AT from baseline to week 9, ad-
justed for baseline, between treatment groups was + 2.9
ml kg−1 min−1; (95%CI 0.8, 5.1), p = 0.011 (Table 2)
(when unadjusted for baseline was + 2.8 (95%CI 0.6,
5.0), p = 0.014). Sensitivity analysis between treatment
groups for a further adjusted effect using linear regres-
sion for age and gender was + 3.4 ml kg−1 min −1;
(95%CI 1.1, 5.7), p = 0.005.
Changes in VO2 at AT throughout the entire cancer
journey: pre-NCRT, post-NCRT (week 0), week 3, 6 and
9 between the treatment groups is graphically presented
in Fig. 2. Changes in all CPET variables between the
groups over the 9-week study period are presented in
Supplementary Appendix 2, Table S1 and individual
graphical plots for changes in VO2 at AT over the 9-
week study period are presented in Appendix 3.
Secondary outcomes
From pre- to post-NCRT, VO2 at AT significantly de-
creased in all participants: − 1.3 ml kg−1 min−1; (95%CI
0.4, 2.3), p = 0.008 (Table 3). Changes in all CPET
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variables between pre- and post-NCRT are presented in
Supplementary Appendix 4, Table S2.
HRQoL
(1) HRQoL questionnaires
From pre- to post-NCRT, there was a significant re-
duction in EORTC Global Health Status − 7.1 (95%CI −
0.8, − 13.5), p = 0.030 and EQ5D usual activities – 8.6
(95%CI 1.4, 52.8), p = 0.020 (Table 3). There were no
other significant changes in HRQoL quantitative mea-
surements between the treatment groups over the 9-
week study period (Table 4).
(2) Semi-structured interviews
Post-NCRT, the semi-structured interviews revealed
that cancer treatment adversely impacted participants
HRQoL. Four main themes (each involving subthemes)
were identified: physical ill-being, social problems, be-
havioural/lifestyle disruptions and psychological ill-
being. However, participation in the 9-week exercise
prehabilitation programme resulted in positive changes
in perceptions in HRQoL. Two main themes (each in-
volving subthemes) were identified: physical well-being




From pre- to post-NCRT, there were no significant differ-
ences in daily step count, 84.3 (95%CI − 1340.5, 1509.1), p
= 0.904, or for sleep efficiency median (interquartile
range) 80.2 (71.3, 85.3) and week 9: 79.1 (67.5, 82.9), p =
0.354 (Table 3). Direct comparison between treatment
groups found no significant difference between week 9
and week 0 using a linear model adjusted for baseline in
daily step count: − 46.3 (95%CI − 2045, 1952), p = 0.877,
or sleep efficiency: − 3.0 (95%CI − 15.2, 9.3), p = 0.919.
There were no significant differences between week 9 and
week 0 for any other physical activity outcomes (Table 4).
Post-operative morbidity survey and cancer staging
Post-operative morbidity survey data for both treatment
groups are reported descriptively in Supplementary Ap-
pendix 6, Table S4 (no formal analyses were conducted).
The response of NCRT for both treatment groups are
reported descriptively in Supplementary Appendix 7
Table S5. Four participants had a complete clinical re-
sponse and did not undergo any surgery.
Fig. 1 Screening and recruitment algorithm
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Safety
There were no serious adverse events. There was one
adverse event attributable to exercise training where a
participant sustained a pre-syncope episode following
one of the exercise sessions. The participant was
reviewed by the hospital medical team and by the
patient’s own general practitioner, with no pause in ex-
ercise training.
Discussion
The EMPOWER trial demonstrates physical fitness
levels and HRQoL were significantly reduced following







Age (years) 64 (14)a 57 (10)a 68 (7)a
Gender (% male) 14 (82%) 12 (75%) 4 (80%)
Smoking (%) current 4 (24%) 2 (13%) 1 (20%)
Body mass index (BMI) (kg/m2) 26 (4) a 26 (3) a 24 (4) a
Past medical history
Heart failure 0 (0%) 0 (0%) 0 (0%)
Diabetes 2 (12%) 1 (6%) 0 (0%)
Ischemic heart disease 0 (0%) 0 (0%) 0 (0%)
Cerebrovascular disease 0 (0%) 0 (0%) 0 (0%)
Cancer staging
Tumor
T2 1 (6%) 2 (13%) 0 (0%)
T3/T3a 9 (53%) 8 (50%) 1 (20%)
T3b 2 (12%) 2 (13%) 0 (0%)
T3c 2 (12%) 1 (6%) 0 (0%)
T3d 0 (0%) 1 (6%) 0 (0%)
T4 3 (18%) 2 (13%) 3 (60%)
Missing 0 (0%) 0 (0%) 1 (20%)
Node
N0 4 (24%) 4 (25%) 0 (0%)
N1 7 (41%) 7 (44%) 3 (60%)
N2 6 (35%) 5 (31%) 1 (20%)
Missing 0 (0%) 0 (0%) 1 (20%)
Metastases
M0 16 (94%) 16(100%) 4 (80%)
M1 1 (6%) 0 (0%) 0 (0%)
Missing 0 (0%) 0 (0%) 1 (20%)
Operation
Abdomino-perineal excision 4 (24%) 3 (19%) 0 (0%)
Anterior resection 8 (47%) 3 (19%) 0 (0%)
Central pelvic exenteration 0 (0%) 2 (13%) 0 (0%)
Hartmann’s and liver resection 1 (6%) 0 (0%) 0 (0%)
No surgery (complete responder) 1 (6%) 3 (19%) 0 (0%)
No surgery (disease progression) 1 (6%) 1 (6%) 3 (60%)
No surgery (drop-out/withdrawn) 2 (12%) 4 (25%) 2 (40%)
Cancer staging is reported using TNM classification (V.5, 1997) with sub-classifications. Central pelvic exenteration included excision of rectum and pelvic side wall
± lymphadenectomy
aAll data are presented as n (%) mean except for age and BMI which are mean (SD)
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NCRT in people with locally advanced rectal cancer.
However, a 9-week exercise prehabilitation programme
offered in local treating hospitals initiated following
completion of NCRT significantly improved these out-
comes compared to the usual care control group.
Effect on the primary outcome: physical fitness
This trial confirms findings from our previous single-
centre study that NCRT significantly reduces physical
fitness in this patient population (West et al. 2014a).
Participation in the 9-week exercise programme,
following completion of NCRT, had a clinically signifi-
cant improvement on physical fitness levels. These im-
provements were evident at weeks 3 and 6 on repeat
CPETs (Fig. 2). Findings may be generalizable to other
surgical cancer patients with a shorter time frame be-
tween diagnosis and surgery. The increase in physical fit-
ness may have clinical importance as the VO2 at AT
reported at week 9 (pre-surgery) is higher than the
previously established cut-off point (11.1 ml kg−1 min−1)
for in-hospital post-operative morbidity (West et al.
2016). Of interest, even before initiating NCRT, the
physical fitness levels of participants’ in the EMPOWER
trial was lower than aged-matched healthy counterparts
(Boereboom et al. 2016). Similarly, lower baseline fitness
levels have also been reported in a breast cancer study
(Peel et al. 2014). Future programmes should intervene
with an exercise programme during the cancer staging
process, as it would allow patients the opportunity to
improve physical fitness levels prior to starting NCRT
and maintain fitness during NCRT. Although the post-
operative morbidity survey data were recorded, the ex-
ploratory nature of the outcome and small sample size
preclude quantitative inference. However, currently, the
WesFit trial (Identifier: NCT03509428) and the PREP
ARE ABC trial (Identifier: ISRCTN8223315) are cur-
rently investigating whether pre-operative exercise train-
ing improves post-operative morbidity.
Table 2 Physical fitness at week 0 and week 9 between exercise and usual care control groups
Physical fitness Week 0, n Week 9, n Difference in endpoint week 9
(95% CI), P value
Primary outcome:
VO2 at AT (ml kg
−1 min −1)
Exercise 11.6 (3.4), 15 15.0 (4.2), 13 2.9 (0.8, 5.1), 0.011
Usual care control 10.8 (2.5), 13 11.5 (2.5), 12
Data are presented as mean (SD)
Abbreviations: VO2 at AT oxygen uptake at anaerobic threshold, n sample of patients assessed
*P < 0.05 was taken as statistically significant. P value adjusted for baseline following linear regression with the difference between week 9 and week 0
Fig. 2 Changes in oxygen uptake at lactate threshold (ml kg−1 min −1) throughout the entire cancer journey: pre-NCRT, post-NCRT (baseline/
week 0), week 3, 6 and 9 between the exercise group and the usual care control group
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Effects on secondary outcome: health-related quality of
life
The EMPOWER trial semi-structured interviews shows
that NCRT adversely impacts HRQoL domains related
to physical, psychosocial and behavioural functioning.
Participants reported experiences of physical ill-being,
social problems, behavioural/lifestyle disruptions and
psychological concerns. Those on the exercise
Table 3 Physical fitness, health-related quality of life (questionnaires) and physical activity pre- and post-neoadjuvant cancer
treatment
Pre-NCRT, n Post-NCRT, n Mean difference (95 % CI) P value
Primary outcome: VO2 at AT (ml kg
−1 min−1) 12.6 (3.3), 28 11.2 (3),28 1.3 (0.4, 2.3) 0.008a *
Secondary outcome: EORTC C30 questionnaire (scale scores between 0 and 100 (best)
Global health status 70.4 (16.2), 27 63.7 (16.2),28 7.1 (0.8, 13.5) 0.030a *
Physical functioning 93.3 (80.0, 100.0), 27 86.7 (73.3, 100).28 0.119b
Emotional functioning 83.3 (66.7, 91.7), 27 75.0 (66.7, 91.7),28 1.2 (− 4.9, 7.3) 0.740a
Fatigue 22.2 (11.1, 33.3), 27 33.3 (22.2, 55.6),28 − 16.5 (− 26.5, − 6.4) 0.002a *
Pain 16.7 (0.0, 33.3), 27 16.7 (0, 33.3),28 − 9.3 (− 20.1, 1.6) 0.092a
Insomnia 33.3 (0.0, 33.3), 27 33.3 (0, 66.6),28 − 11.1 (− 20.8, − 1.4) 0.026a *
EQ5D questionnaire: usual activities Pre-NCRT, n Post-NCRT, n Odds ratio (95% CI) P value
No problems doing usual activity 18 (67%), 27 14 (50%),28 8.6 (1.4, 52.8) 0.020a *
Slight problems doing my usual activity 7 (26%), 27 8 (28.6%),28
Moderate problems doing usual activity 2 (7.4%), 27 5 (17.9%),28
Severe problems doing usual activity 0 (0%), 27 1 (3.6%),28
Self-care
No problems washing or dressing 26 (96.3%), 27 26 (92.9%),28 2.4 (0.2, 28.4) 0.476a
Slight problems washing or dressing 1 (3.7%), 27 1 (3.6%),28
Moderate problems washing or dressing 0 (0%), 27 1 (3.6%),28
Pain/discomfort
No pain or discomfort 10 (37.0%), 27 8 (28.6%),28 0.8 (0.3, 2.4) 0.721a
Slight pain or discomfort 11 (40.7%), 27 15 (53.6%),28
Moderate pain or discomfort 5 (18.5%), 27 5 (18.9%),28
Severe pain or discomfort 1 (3.7%), 27 0 (0%),28
Anxiety/depression
Not anxious or depressed 14 (51.9%), 27 15 (53.6%),28 0.6 (0.2, 2.2) 0.478a
Slightly anxious or depressed 8 (29.6%), 27 11 (39.3%),28
Moderately anxious or depressed 4 (14.8%), 27 1 (3.6%),28
Severely anxious or depressed 1 (3.7%), 27 1 (3.6%),28
Health scale (between 0 and 100 (best) 74.8 (16.8), 27 70.9 (14.4),28 4.2 (− 1.4, 9.9) 0.121a
Exploratory outcome: physical activity
Step count 5276 (3590, 8648), 22 5641 (3602, 8929),25 84.3 (− 1340.5, 1509.1) 0.904a
Sleep efficiency (%) 79.1 (69.6, 85.0), 21 79.1 (67.5, 82.9),25 0.354b
PA duration (min/day) 52.5 (28.7, 108.0), 22 70.3 (28, 121),25 − 0.2 (− 20.0, 19.5) 0.982a
Energy expenditure (kcal/day) 2258.3 (629.7), 22 2419.8 (593.5),25 − 37.5 (− 199.8, 124.8) 0.636a
Sleep duration (min/day) 391.1 (118.7), 22 377.3 (79.6),25 9.6 (− 40.9, 60.1) 0.697a
Average METS 1.4 (0.3), 22 1.3 (0.2),25 0.02 (− 0.07, 0.1) 0.593a
Abbreviations: VO2 at AT oxygen uptake at anaerobic threshold, VO2 at Peak oxygen uptake at peak exercise, PA physical activity, METS metabolic equivalent
threshold, n sample of patients assessed
Note: physical activity data is mean over 3 days
Data are presented as mean (SD), median (IQR) or n (%)
*P < 0.05 was taken as statistically significant
aP value following paired sample t tests
bP value following Wilcoxon signed-rank tests
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programme experienced positive changes in perceptions
of physical well-being and psychological well-being. To
our knowledge, no other study has explored this through
semi-structured interviews apart from our preliminary
work in the same population (Burke et al. 2013), where
we showed that participants experiened improved vital-
ity, a positive attitude, enhanced social connections and
a sense of purpose in life a 6-week pre-operative exercise
Table 4 Physical fitness, health-related quality of life (questionnaires) and physical activity at week 0 and week 9 between exercise
and usual care control groups
Exercise Usual Care Control P value
Week 0, n Week 9, n Week 0, n Week 9, n
Secondary outcome: EORTC C30 questionnaire (scale scores between 0 and 100 (best)
Global health status 63.9 (16.6),15 77.8 (13.0),12 63.5 (16.5),13 72 (19.5),11 0.668 a
Physical functioning 86.7 (73.3, 100.0),15 100 (86.7, 100.0), 2 86.7 (66.7, 93.3),13 86.7 (86.7, 100),11 0.782b
Emotional functioning 75.0 (66.7, 100.0),15 95.8 (66.7, 100.0),12 75.0 (66.7, 83.3),13 75.0 (50, 83.3),11 0.132a
Fatigue 33.3 (11.1, 55.6),15 11.1 (0.0, 33.3),12 33.3 (22.2, 55.6),13 11.1 (0, 33.3),11 0.603a
Pain 16.7 (0.0, 33.3),15 0 (0.0, 8.3),12 16.7 (16.7, 33.3),13 16.7 (0, 33.3),11 0.708b
Insomnia 33.3 (0.0, 66.7),15 16.7 (0.0, 33.3),12 33.3 (0.0, 66.7),13 33.3 (0, 33.3),11 0.248a
EQ5D questionnaire: usual activities
No problems doing usual activity 8 (53%),15 6 (46%),12 9 (75%),13 7 (64%),11 0.630a
Slight problems doing usual activity 4 (27%),15 4 (31%),12 3 (25%),13 4 (36%),11
Moderate problems doing usual activity 2 (13%),15 3 (23%),12 0 (0%),13 0 (%),11
Severe problems doing usual activity 1 (7%),15 0 (0%),12 0 (0%),13 0 (0%),11
Self-care
No problems washing/dressing 15 (100%),15 11 (85%),12 12 (100%),13 10 (91%),11 0.491
Slight problems washing/dressing 0 (0%),15 1 (8%),12 0 (0%),13 1 (9%),11
Moderate problems washing/dressing 0 (0%),15 1 (8%),12 0 (%),13 0 (0%),11
Pain/discomfort
No pain or discomfort 4 (27%),15 4 (31%),12 9 (75%),13 5 (45%),11 0.512a
Slight pain or discomfort 9 (60%),15 6 (46%),12 2 (17%),13 4 (36%),11
Moderate pain or discomfort 2 (13%),15 3 (23%),12 1 (8%),13 2 (18%),11
Anxiety/depression
Not anxious or depressed 10 (67%),15 5 (38%),12 9 (75%),13 5 (45%),11 0.111a
Slightly anxious or depressed 4 (27%),15 7 (54%),12 3 (25%),13 4 (36%),11
Moderately anxious or depressed 1 (7%),15 0 (0%),12 0 (0%),13 1 (9%),11
Severely anxious or depressed 0 (0%),15 1 (8%),12 0 (0%),13 0 (0%),11
Extremely anxious or depressed 0 (0%),15 0 (%),12 0 (0%),13 1 (9%),11
Health scale (between 0 and 100 (best) 69.6 (14),15 72.4 (15.2),12 78.8 (14),13 75.1 (20.3),11 0.040a *
Exploratory outcome: physical activity
Step count 7058 (4981),12 7023 (5562),11 6321 (3456),13 6749 (2959),12 0.877a
Sleep efficiency (%) 74.5 (8.3),12 72.1 (13.2),11 75.7 (10.5),13 74.4 (12.8),12 0.919a
Energy expenditure (kcal/day) 2467 (676), 12 2326 (639),11 2376 (530),13 2424 (559),12 0.145a
PA duration (min/day) 96.9 (79.5),12 89.5 (81.8),11 70.8 (51.2),13 81.2 (43.8),12 0.313a
Sleep duration (min/day) 380.4 (75.7),12 373.9 (82.8),11 374.5 (86.1),13 361.6 (98.5),12 0.803a
Average METS 1.4 (0.2),12 1.4 (0.2),11 1.3 (0.2),13 1.3 (0.2),12 0.525a
Note: physical activity data is mean data over 3 days
Data are presented as mean (SD) or median (IQR) except EQ5D data which is presented as n (%)
Abbreviations: PA physical activity, METS metabolic equivalent threshold, n sample of patients assessed
*P < 0.05 was taken as statistically significant
aP value following linear regression with the difference between week 9 and 0 adjusted for baseline
bP value following Wilcoxon Mann-Whitney test
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training (Burke et al. 2013). Additionally, the EM-
POWER trial also shows that the 9-week exercise pre-
habilitation programme had a significant improvement
on participants’ health status and usual activities.
These positive HRQoL findings at week 9 may be of
importance as psychological variables are associated
with early surgical recovery (Mavros et al. 2011). To
our knowledge, no studies have investigated the ef-
fects of exercise prehabilitation on HRQoL and surgi-
cal outcome. However, this area is emerging with the
development of prehabiliation programmes which aim
to optimise physical fitness, nutritional and psycho-
logical outcomes pre-operatively.
Effect on the exploratory outcome: physical activity
The EMPOWER trial shows no significant changes in
physical activity following NCRT or the exercise prehabili-
tation programme. At present, little is known about ob-
jective physical activity levels in this regard. To our
knowledge, our previous pilot study was the first to report
this in a non-randomised controlled trial. We showed that
NCRT significantly reduced daily step count however par-
ticipating in a 6-week exercise programme immediately
following NCRT significantly improved physical activity
outcome measures for sleep efficiency and duration. Con-
tributing factors to the difference in these findings from
our pilot study and the EMPOWER trial may be due to
the difference in pre-NCRT daily step count (higher in the
EMPOWER trial), study design (RCT vs. a single centre
non-randomised contemporaneous controlled study) and
comorbidity (50% of participants in the previous pilot
study had comorbid disease compared to 8% in the EM-
POWER trial). The physical activity data in EMPOWER
does suggest however that the positive findings presented
for physical fitness are attributable to the structured exer-
cise training programme and not due to any significant
changes in physical activity over the 9-week period. Inter-
estingly, in both our initial pilot work and EMPOWER, we
reported a low metabolic equivalent threshold (MET)
scores across the cancer care pathway (from diagnosis to
surgery), suggestive of light intensity activity. This may be
clinically important: a MET score of 27 MET-hours per
week in men with colorectal cancer is associated with a
50% reduced risk of colorectal cancer-specific mortality
and overall mortality, compared with engaging in < 3
MET-hours/week (Meyerhardt et al. 2006). The MET
score at week 0 and week 9 in both groups equates to be-
tween 9.1 and 9.8 MET-hours per week which is almost
60% less than that reported for disease-free survival bene-
fits. Perhaps there is a role for issuing physical activity
monitors at outpatient clinic at the point of cancer diag-
nosis and educate patients on the importance of moderate
intensity physical activity.
Strengths and weaknesses of this study
Strengths of this multi-centre RCT include a homoge-
neous group including MRI defined circumferential mar-
gin threatened (locally advanced) rectal cancer patients,
the novel in-hospital programme with a clearly defined
exercise intervention, prescribed individually, with train-
ing intensities derived and reported by two assessors.
CPET used a constant protocol and software; analysis
was by two independent physiological assessors blind to
group allocation, all outcome data and independent of
the intervention; and the multi-disciplinary team caring
for the patients were not provided with any information
regarding predictive measures (CPET variables). Add-
itionally, the inclusion of the HRQoL which was col-
lected at the same time points as CPET. Physical activity
was measured in an objective manner using validated
SenseWear activity monitors; participants in the exercise
group did not wear the physical activity monitors during
exercise sessions, allowing for accurate comparisons be-
tween the groups. Randomization was computerized.
Data were handled using a double-entry data system.
The statisticians conducting the analyses were blind to
the group allocation until after the analysis was
complete.
Weaknesses are that the target sample size was not
achieved. This is mainly due to a change in treatment
pathways at recruiting sites during the trial conduct: a
lower number of patients undergoing long-course NCRT
and surgery than originally forecasted became apparent
(note: some NHS trusts have a variation of NCRT op-
tions for MRI threatened rectal cancer, i.e. short course
NCRT with a short waiting time to surgery or neoadju-
vant systemic chemotherapy prior to NCRT with a vari-
able wait time between the end of NCRT and surgery).
To overcome this challenge, the recruitment period was
extended for an additional year (from December 2015 to
December 2016) and three additional sites were invited
to participate from 2014 to 2015 (recruitment initially
started in University Hospital Southampton and Univer-
sity Hospital Aintree in 2013/2014). Therefore, the na-
ture of this underpowered trial increases the false
negative rate. Future work may benefit from involving
an implementation scientist as part of the co-design of
prehabilitation studies. Potential weaknesses also lie in
the high dropout rate, the heterogeneity of the NCRT
regimen (due to a change in clinical treatment pathway
during the study period in University Hospital South-
ampton). Additionally, the recruitment uptake rate was
48%. Although there is limited literature published in
the neoadjuvant setting to make comparisons against,
one previous study in the same study setting reported a
recruitment uptake rate of 56% (Morielli et al. 2016b).
Additionally, the high risk of performance and detection
bias as both participants and personnel were not
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blinded, and the sample population largely consisted of
males. Data reporting nutrition, sarcopenia, anaemia and
preoperative inflammation outcomes were not recorded
as part of this study, all of which would have been added
to the study.
Conclusions
NCRT significantly reduced physical fitness levels and
HRQoL. A 9-week exercise prehabilitation programme
initiated following NCRT resulted in a clinical and sig-
nificant increase in VO2 at AT and had a positive effect
on HRQoL compared to a usual care control group. The
findings from the EMPOWER trial informed the WesFit
trial that is currently investigating whether fitness, be-
haviour change support and emotional support pro-
grammes delivered in the community can boost recovery
rates after major cancer surgery (in collaboration with
Wessex Cancer Alliance). As hospital-based programmes
have been impacted during the COVID-19 pandemic,
such community programmes are important to
investigate.
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